

10/590342

IAP12 Rec'd PCT/PTO 24 AUG 2006

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : To be assigned
(U.S. national phase of
PCT/JP2004/002124)

Applicants : Keiji HASUMI et al.

Filed : Concomitantly Herewith

For : ANTICANCER AGENT CONTAINING
BL-ANGIOSTATIN

Docket No. : 06506/HG

Customer No.: 01933

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP PCT

S I R :

Submitted herewith are the following:

(1) A copy of the International Search Report (in English)
which issued in the PCT/JP2004/002124;

(2) Forms PTO/SB/08A and PTO/SB/08B. It is respectfully
request that initialed copies of the enclosed Forms PTO/SB/08A
and PTO/SB/08B be returned to indicate that the publications
listed therein have been considered and made of record; and

(3) Copies of the publications cited in said Forms
PTO/SB/08A and PTO/SB/08B.


Each of the publications cited in the enclosed International
Search Report is considered relevant or material to the

Express Mail Mailing Label

No.: EV 902 109 138 US

Date of Deposit: AUGUST 24, 2006

I hereby certify that this paper is being
deposited with the United States Postal
Service "Express Mail Post Office to
Addressee" service under 37 CFR 1.10 with
sufficient postage on the date indicated
above and is addressed to the Commissioner
for Patents, Arlington, VA 22313-1450


Dorothy DeFrancesco

In the event that this Paper is late filed,
and the necessary petition for extension of
time is not filed concurrently herewith,
please consider this as a Petition for the
requisite extension of time, and to the
extent not tendered by a Form PTO 2038
attached hereto, authorization to charge the
extension fee, or any other fee required in
connection with this Paper to Account No.
06-1378.

patentability of the present application in view of the citation thereof in said International Search Report.

Said International Search Report is in English, thereby satisfying the requirements for a concise explanation of relevance for the publications cited therein.

The publications cited on said Forms PTO/SB/08A and PTO/SB/08B were either identified on the enclosed International Search Report or disclosed on pages 1 to 3 of the specification.

PCT/JP03/00338, which is disclosed in the first full paragraph on page 3 of the present specification, is identified on the enclosed Form PTO/SB/08A as WO 2004/065595.

JP 2002-272453 is disclosed in the paragraph bridging pages 2 and 3 of the specification and is also cited in the enclosed International Search Report.

It is respectfully requested that the attached publications be considered and made of record

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
200 FIFTH AVENUE - 16TH FLOOR
NEW YORK, NEW YORK 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf
Enclosures:

- (1) a copy of the International Search Report for
PCT/JP2004/002124
- (2) Forms PTO/SB/08A and PTO/SB/08B and copies of the
publications cited therein

10/590342

Please type a plus sign (+) inside this box →



IAP12 Rec'd PCT/PTO 24 AUG 2006

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		U.S. National Phase of PCT/JP2004/002124	
				Filing Date		Concomitantly Herewith	
				First Named Inventor		Keiji HASUMI	
				Group Art Unit			
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number		06506/HG	

U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

FOREIGN PATENT DOCUMENTS

Exam Inits*	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
		WO	2004/065595	A1	TTC CO., LTD.	08-05-2004		
		WO	96/35774	A2	THE CHILDREN'S MEDICAL CENTER CORPORATION	11-14-1996		
		WO	98/54217	A1	THE CHILDREN'S MEDICAL CENTER CORPORATION	12-03-1998		
		JP	9-286798	A	JURIDICAL FOUNDATION, THE CHEMO-SERO- THERAPEUTIC RESEARCH INSTITUTE	11-04-1997		
		JP	2002-272453	A	JAPAN SCIENCE & TECHNOLOGY CORP.	09-24-2002		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: August 24, 2006

10/590342

Please type a plus sign (+) inside this box →



IAP12 Rec'd PCT/PTO 24 AUG 2006

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	U.S. National Phase of PCT/JP2004/002124
				Filing Date	Concomitantly Herewith
				First Named Inventor	Keiji HASUMI
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	06506/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		<p>Michael S. O'REILLY et al., "Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <u>Cell</u>, <u>79</u>, 315-328, (1994)</p> <p>Michael S. O'REILLY et al., "Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice," <u>Nature Medicine</u>, <u>2</u>, 689-692, (1996)</p> <p>B. Kim Lee SIM et al., "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer", <u>Cancer Research</u>, <u>52</u>, 1329-1334, (1997)</p> <p>Yihai CAO, "Endogenous Angiogenesis Inhibitors and Their Therapeutic Implications," <u>The International Journal of Biochemistry & Cell Biology</u>, <u>33</u>, 357-369, (2001)</p> <p>Raffaella DELL'EVA et al., "Inhibition of Tumor Angiogenesis By Angiostatin: From Recombinant Protein to Gene Therapy", <u>Endothelium</u>, <u>9</u>, 3-10, (2002)</p> <p>Kousuke SHIMIZU et al., <u>Japan Society for Bioscience, Biotechnology, and Agrochemistry</u>, Vol. 2003, page 258, (2003)</p>	
Examiner Signature		Date Considered	

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: August 24, 2006